The FDA and Health Canada cleared a couple medical devices while other companies touted their device studies. Here are 7 medtech stories we missed this week but were still worth mentioning. 1. FDA clears Medela’s neonatal enteral feeding device Medela has received 510(k) clearance from the FDA to market its ENFit Low Dose Tip eternal […]
Pavmed
Pavmed announces upcoming exchange offering
Pavmed (NSDQ:PAVMU) today announced an upcoming registered exchange offering, looking to make its common stock exchangeable for units. Each unit in the offering from the New York-based company will be comprised of a share of common stock and a newly issued warrant, which will be exercisable for a share of common stock at an exercise price […]
PAVmed raises $1.5m in private placement
PAVmed Inc. (NSDQ:PAVMU) said today it raised $1.5 million through a private placement of Series A convertible preferred stock and Series A warrants, with funds slated to support FDA clearance of its 1st product, the PortIO intraosseous infusion system. The New York-based company said it is hopeful for for FDA 510(k) clearance for the PortIO by the […]
PAVmed partners with Boston institutions for antibiotic-eluting ear device
PAVmed Inc. (NSDQ:PAVMU) said today that it inked an exclusive licensing agreement with academic institutions to develop and commercialize antibiotic-eluting resorbable ear tubes based on an aqueous silk technology designed by the institutions. The licensing deal includes agreements with Tufts University, Massachusetts Eye & Ear Infirmary and Massachusetts General Hospital, who developed the aqueous silk technology. As […]
Haemonetics taps ex-Medtronic CIO Burke as new CFO | Personnel Moves August 4, 2016
Haemonetics taps ex-Medtronic CIO Burke as new CFO Haemonetics (NYSE:HAE) said this week it tapped former Medtronic (NYSE:MDT) chief integration officer William Burke as its new chief financial officer, effective August 8. Burker operated as CIO with Medtronic since 2015, serving during the integration of Covidien. Prior to that, he held various finance positions with […]
Pavmed eyes Q4 FDA submission for PortIO vascular access device
Pavmed (NSDQ:PAVMU) said today that it’s planning to submit an application for FDA clearance for its 1st product, the PortIO long-term implantable vascular access device, during the 4th quarter. New York City-based Pavmed said the PortIO device is in the verification and validation testing phase, the final stage of pre-submission testing. The company has 4 other […]
Pavmed IPO grosses $5.3m
Updated with the correct stock ticker for currently trading Pavmed units (PAVMU) Pavmed said today that its initial public offering grossed $5.3 million, after extending the flotation last month for an extra 45 days. Pavmed is developing devices in 5 areas, according to its IPO registration: The PortIO long-term implantable vascular access device; the Caldus line […]
Pavmed extends $6m IPO
Pavmed said earlier this week it will extend its heavily reduced $6 million IPO an additional 45 days. The IPO was dramatically reduced in January, with the company announcing that it planned to float a reduced 1.2 million shares at $5 a piece. Pavmed expects the IPO to bring in $5.4 million after sales commissions but […]
Pavmed scales back IPO to $6m
Pavmed last week dramatically trimmed its pending initial public offering, saying it plans to float 1.2 million shares at $5 apiece for gross proceeds of $6 million. That’s a far cry from the $23 million top end Pavmed listed when it registered the IPO last May. Pavmed is developing devices in 5 areas, according to its […]
BSX aims for double-digit earnings growth | Medtech Wall Street news for the week of May 4, 2015
Pavmed files for $23m IPO
The entrepreneurs behind a quartet of medical device companies is betting their formula can cut down on the time and cost of getting medtech to market with a $23 million initial public offering.
